🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）

Recruitingn/aAges 18 Years - anyAllBeijing Tiantan Hospital
NCT05975398 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Although emergency surgery may reduce mortality in patients with severe spontaneous intracerebral hemorrhage (SSICH), the effectiveness and safety of surgical treatment among SSICH patients receiving long-term oral antiplatelet therapy (LOAPT) remain unclear. The CRISIH registry was originally designed to evaluate the effect and safety of emergency surgery in SSICH patients receiving LOAPT and has subsequently continued as an ongoing multicenter registry of spontaneous intracerebral hemorrhage. Methods: The CRISIH registry is an ongoing prospective, multicenter cohort registry conducted across participating clinical centers in China. The registry was initiated in November 2019 and is designed as a 10-year registry with continued recruitment and follow-up. Data from the initial five-year enrollment period are used for interim and secondary analyses, while recruitment and foll

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18 years or older. 2. Spontaneous, nontraumatic intracerebral hemorrhage. 3. Treatment with surgical or conservative management according to clinical indications and routine clinical practice. 4. Written informed consent provided by the patient or legally authorized representative/family member. Exclusion Criteria: 1. Patients had cerebrovascular diseases associated with hemorrhage, such as intracranial aneurysm, cerebrovascular malformation, or intracranial tumors. 2. Hemorrhagic transformation of cerebral infarction. 3. Hemorrhage caused by cerebral venous thrombosis. 4. Patients with severe coagulation disorder, such as hemophilia. 5. Patients with coagulation dysfunction caused by malignant tumor, hepatic insufficiency, renal dysfunction, thrombocytopenia, coagulation diseases, or related conditions. 6. Patients receiving other anticoagulation medications, including vitamin K antagonists or novel oral anticoagulants. 7. Patients who died before arrival at the hospital, on arrival at the hospital, or within a short period (6 hours) after admission.
💊

What it tests

  • Emergency neurosurgery
  • Conservative treatment
📍

Where

1 site
Capital Medical University Affiliated Beijing Tiantan Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy